IZIPRY™ (former OX124) is a late-stage, high dose nasal powder with naloxone to be used in life-threatening situations where the overdose on any opioid is suspected, indicated by e.g. unconsciousness or opioid-induce respiratory depression (OIRD). Izipry is developed based on the AmorphOX® technology.
OX390 is a New Chemical Entity (NCE) with a novel formulation and route of administration, supported by the AmorphOX technology. It is intended to reverse respiratory depression from adulterated overdoses. Orexo is developing, OX390, in partnership with BARDA.1
OX125 is an early-stage powder-based formulation of nalmefene for intranasal administration in life-threatening situations where the overdose on any opioid is suspected. Nalmefene has a prolonged half-life compared to naloxone and may potentially last longer than the majority of highly potent synthetic opioids. OX125 is developed based on the AmorphOX technology.
1 Biomedical Advanced Research and Development Authority